hypercholesterolaemia with cardiovascular risk
Metabolic · 2006–2009
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ezetimibe with simvastatin Treatment in conjunction with dietary therapy and exercise in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor… | Mar 2009 | Recommended with restriction | no section in document |
| ezetimibe Treatment of patients with hypertension or family history of coronary heart disease who have inadequately controlled cholesterol levels despite statin therapy,… | Nov 2006 | Recommended with restriction | no section in document |
What the PBS pays
$115M in government benefit over 2024–25, across 7,059,842 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ezetimibe with simvastatin | $65M |
| ezetimibe | $49.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.